Increased Biotechnology Funding
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
2010 Commonwealth Games ~ 2010 Nobel Prizes ~ Sachin Tendulkar ~ Rajasthan Royals ~ Kings XI Punjab ~ Sushil Kumar ~ Deepika Kumari ~ Somdev Devvarman ~ HR Bhardwaj
Home / India News / 2007 / March / March 9, 2007
Increased Biotechnology Funding Boosts U.S. Drug Discovery Contract Research Organization Markets

Top News

144 Section in Hyderabad ahead of Ayodhya verdict

Manmohan Singh to campaign in Bihar today

FBI failed to act on Headley's wife's terror link expose 3 yrs before Mumbai attacks

Craven's horror flicks 'were inspired by real stories'

RBI will intervene if inflows turn lumpy: Subbarao

Enforcement Directorate issues 'Look Out Circular' against Lalit Modi

Now, laser technology that destroys tumours using heat

Waist size, not BMI can foretell cardiovascular risk in children

Increased Biotechnology Funding Boosts U.S. Drug Discovery Contract Research Organization Markets

Mumbai, Maharashtra, India

The contract research organization (CRO) market presents a mix of numerous challenges and opportunities and is likely to provide pharmaceutical and biotechnology market participants the opportunity to achieve their strategic objectives by offering services that seek to reduce cost and time-to-market drug candidates. CROs are likely to capitalize on this tremendous opportunity by pursuing a mix of organic and inorganic growth initiatives that will ensure greater penetration of the market and higher share of R&D spending.

New analysis from Frost & Sullivan (, U.S. Drug Discovery Contract Research Organization Markets, reveals that the market earned revenues of $7.44 billion in 2006 and is likely to reach $19.35 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Drug Discovery Contract Research Organization Markets, then send an e-mail to Shwetha Thomas - Corporate Communications at with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

Biotechnology and pharmaceutical companies are outsourcing their R&D to CROs due to the lack of internal expertise, infrastructure, mounting costs of drug development, and stringent regulatory guidelines. Biotechnology companies have limited investments in development infrastructure compared to their pharmaceutical counterparts. This is resulting in greater business volumes for CROs from the biotechnology market.

"The increase in globalization of trials is likely to result in several CROs expanding across geographical boundaries and augmenting their capacity to cater to this opportunity," notes Frost & Sullivan Research Analyst Barath Shankar S. "As the market continues to enlarge and inorganic growth emerges as a critical component of this expansion, the trend of deepening focus on core expertise is becoming crucial."

Along with offering required expertise to manage complex global trials across a variety of therapeutic segments, CROs provide a full line of preclinical and clinical services, which aid rapid expansion of the drug discovery CRO market. Their ability to deliver clinical trial participants with high levels of efficiency and productivity are further strengthening the need for companies to outsource R&D.

Several leading CROs have proactively established global presence through a strategic mix of organic and inorganic growth strategies. Achieving the right breadth and depth of services can prominently position these CROs in the highly competitive and rapidly growing market.

Market participants can gain prominence by shifting from the traditional route of drug discovery to the emerging "proof of concept" model. The complexity of the drug discovery process necessitates high degree of technical change to drive innovation and achieve greater efficiency in commercially launching products.

"However, there is an increasing level of commoditization of CRO services due to similarity in quality and range of services provided," observes Shankar. "CROs can benefit from offering cost-effective services to retain companies likely to change loyalties based on lower cost benefit."

The U.S. Drug Discovery Contract Research Organization Markets is part of the Pharmaceuticals and Biotechnology subscription, which also includes research in the following markets: global pharmaceutical contract manufacturing, analysis of top 10 specialty pharmaceutical companies, and global vaccines. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Analyst interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit

U.S. Drug Discovery Contract Research Organization Markets

Shwetha Thomas, Corporate Communications - South Asia & Middle East, Frost & Sullivan, +91 (022) 4001 3429

Melina Trevino, Corporate Communications - North America, Frost & Sullivan, +210 247 2440

Source: Frost & Sullivan (Business Wire India)

Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.

India News / Press Releases on March 9, 2007

Mounting Accident and Insurance Costs Impel Demand in North American Class 6-8 Truck OE Safety Systems Market
Business Wire India

Enteral Nutrition: Bypassing Barriers to Success
Business Wire India

Increased Biotechnology Funding Boosts U.S. Drug Discovery Contract Research Organization Markets
Business Wire India

"An IDEA Whose Time has Come" - Mr. Kumar Mangalam Birla, Chairman, Idea Cellular
Business Wire India

ISB Hosts Asia Semi Final of the Global Social Venture Competition
Business Wire India

Also see International News / Press Releases on March 9, 2007

Suggested pages for your additional reading on Facebook

© 2000-2017 All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us